Logo

AstraZeneca Selects Cancer Target under Regulus Partnership

Oct 31, 2013
Premium

Regulus Therapeutics this week announced that AstraZeneca has selected an undisclosed oncology target under the companies' ongoing partnership to develop microRNA-targeting drugs for oncology and cardiovascular and metabolic diseases.

The companies began working together last year, agreeing to co-develop and –commercialize miRNA drugs against three exclusive targets, including potentially miRNA-33 in atherosclerosis (GSN 8/16/2012).

Regulus received $28 million upfront, which included an equity investment, and stands to be paid milestones and royalties.

Filed under

Gene Editing, Gene Silencing, & CRISPR
Cancer
Regulus
AstraZeneca
RNAi
miRNA
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.